247 related articles for article (PubMed ID: 11249473)
1. Prostate-specific antigen.
Ornstein DK; Pruthi RS
Expert Opin Pharmacother; 2000 Dec; 1(7):1399-411. PubMed ID: 11249473
[TBL] [Abstract][Full Text] [Related]
2. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
3. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Bretton PR; Evans WP; Borden JD; Castellanos RD
Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
[TBL] [Abstract][Full Text] [Related]
4. Improving the Specificity of PSA Screening with Serum and Urine Markers.
Kearns JT; Lin DW
Curr Urol Rep; 2018 Aug; 19(10):80. PubMed ID: 30105509
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
7. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Amirkhan A; Horninger W; Klocker H; Mikolajczyk SD
J Urol; 2003 Dec; 170(6 Pt 1):2181-5. PubMed ID: 14634374
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
[TBL] [Abstract][Full Text] [Related]
9. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
11. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
[TBL] [Abstract][Full Text] [Related]
12. [The role of prostate specific antigen and its derivatives (age-specific PSA, PSA density, velocity, free/total PSA) in the diagnosis of prostate cancer].
Di Silverio F; D'Eramo G; Buscarini M; Sciarra A; Casale P; Di Nicola S; Loreto A
Minerva Urol Nefrol; 1998 Jun; 50(2):143-54. PubMed ID: 9707970
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
14. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
[TBL] [Abstract][Full Text] [Related]
15. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
[TBL] [Abstract][Full Text] [Related]
16. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy.
Ruckle HC; Klee GG; Oesterling JE
Mayo Clin Proc; 1994 Jan; 69(1):69-79. PubMed ID: 7505870
[TBL] [Abstract][Full Text] [Related]
18. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
Nordström T; Adolfsson J; Grönberg H; Eklund M
BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
[TBL] [Abstract][Full Text] [Related]
19. [Status of PSA determination for early detection of prostate carcinoma].
Hammerer P; Huland H
Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
